(Q37775820)

23 August 2017

1 reference

title

Darapladib: an emerging therapy for atherosclerosis (English)

1 reference

23 August 2017

1 reference

Marshall A Corson

1

1 reference

23 August 2017

publication date

26 July 2010

1 reference

Therapeutic advances in cardiovascular disease

23 August 2017

published in

1 reference

23 August 2017

volume

4

1 reference

23 August 2017

issue

4

1 reference

23 August 2017

page(s)

241-248

1 reference

Effects of combination lipid therapy in type 2 diabetes mellitus

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1753944710375820

The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710375820

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710375820

Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710375820

Use of biomarkers to develop treatment strategies for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710375820

Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710375820

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710375820

In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710375820

Plasma platelet activating factor-acetylhydrolase (PAF-AH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710375820

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710375820

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710375820

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710375820

The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, dou

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710375820

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710375820

The phospholipase A2 superfamily and its group numbering system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710375820

Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710375820

New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710375820

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710375820

Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710375820

Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710375820

21 January 2018

Identifiers

DOI

10.1177/1753944710375820

1 reference

23 August 2017

1 reference